Orchestra Biomed Holdings, Inc. ( (OBIO) ) has released its Q3 earnings. Here is a breakdown of the information Orchestra Biomed Holdings, Inc. presented to its investors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Orchestra Biomed Holdings, Inc. is a biomedical innovation company that partners with leading medical device companies to develop and commercialize high-impact healthcare technologies, focusing on treatment solutions for hypertension and artery disease. In its latest quarterly earnings report, Orchestra Biomed reported a net loss of $15.4 million for the third quarter of 2024, an increase from the $13.3 million net loss in the same period of 2023. The company’s revenue totaled $987,000 for the quarter, driven by partnership and product revenues. Despite the losses, the company successfully raised $15 million through an At-The-Market offering, strengthening its financial position. Looking ahead, Orchestra Biomed remains focused on advancing its product candidates towards commercialization, leveraging its strategic partnerships to achieve its development goals.
